


Recombinant SARS-CoV-2 B.1.617 Spike (GCN4-IZ) His-tag

Catalog Number: 10861-CV

DESCRIPTION				
Source	Human embryonic kidney cell, HEK293-derived sars-cov-2 Spike protein			
	Recombinant SARS-CoV-2 Spike (Val16-Lys1211)(Gly142Asp, Glu154Lys, Leu452Arg, Glu484Gln, Asp614Gly, Pro681Arg, Gln1071His)(Arg682Ser, Arg685Ser, Lys986Pro, Val987Pro) Accession # YP_009724390.1	GCN4-IZ	6-His tag	
	N-terminus		C-terminus	
N-terminal Sequence Analysis	Val16			
Predicted Molecular Mass	138 kDa			

SPECIFICATIONS		
SDS-PAGE	139-167 kDa, under reducing conditions.	
Activity	Measured by its binding ability in a functional ELISA with Recombinant Human ACE-2 His-tag (Catalog # 933-ZN).	
Endotoxin Level	<0.10 EU per 1 μ g of the protein by the LAL method.	
Purity	>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.	
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.	


PREPARATION AND STORAGE		
Reconstitution	Reconstitute at 500 µg/mL in PBS.	
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.	
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles.	
	 12 months from date of receipt, -20 to -70 °C as supplied. 	
	 1 month, 2 to 8 °C under sterile conditions after reconstitution. 	
	• 3 months -20 to -70 °C under sterile conditions after reconstitution	



DATA

Recombinant SARS-CoV-2 B.1.617 Spike (GCN4-IZ) Histag Protein Binding Activity. Recombinant SARS-CoV-2 B.1.617 Spike (GCN4-IZ) Histag (Catalog # 10861-CV) binds Recombinant Human ACE-2 Histag (Catalog # 933-ZN) in a functional ELISA.

SDS-PAGE



Recombinant SARS-CoV-2 B.1.617 Spike (GCN4-IZ) His-tag Protein SDS-PAGE. 2 µg/lane of Recombinant SARS-CoV-2 B.1.617 Spike (GCN4-IZ) His-tag Protein (Catalog # 10861-CV) was resolved with SDS-PAGE under reducing (R) and nonreducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 139-167 kDa.

Rev. 6/1/2021 Page 1 of 2



Global bio-techne.com info@bio-techne.com techsupport@bio-techne.com TEL +1 612 379 2956 USA TEL 800 343 7475 Canada TEL 855 668 8722 China TEL +86 (21) 52380373 Europe | Middle East | Africa TEL +44 (0)1235 529449



Recombinant SARS-CoV-2 B.1.617 Spike (GCN4-IZ) His-tag

Catalog Number: 10861-CV

BACKGROUND

SARS-CoV-2, which causes the global pandemic coronavirus disease 2019 (Covid-19), belongs to a family of viruses known as coronaviruses that also include MERS and SARS-CoV-1. Coronaviruses are commonly comprised of four structural proteins: Spike protein (S), Envelope protein (E), Membrane protein (M) and Nucleocapsid protein (N) (1). The SARS-CoV-2 S protein is a glycoprotein that mediates membrane fusion and viral entry. The S protein is homotrimeric, with each ~180-kDa monomer consisting of two subunits, S1 and S2 (2). In SARS-CoV-2, as with most coronaviruses, proteolytic cleavage of the S protein into S1 and S2 subunits is required for activation. The S1 subunit is focused on attachment of the protein to the host receptor while the S2 subunit is involved with cell fusion (3-5). A metallopeptidase, angiotensin-converting enzyme 2 (ACE-2), has been identified as a functional receptor for SARS-CoV-2 through interaction with a receptor binding domain (RBD) located at the C-terminus of S1 subunit (6, 7). The S protein of SARS-CoV-2 shares 75% and 29% amino acid sequence identified as a prevalent strain in India (8, 9). Whether these mutations in RBD would cause more severe symptom or decrease the efficacy of vaccine-induced immunity is still under investigation.

References:

- 1. Wu, F. et al. (2020) Nature 579:265.
- 2. Tortorici, M.A. and D. Veesler (2019) Adv. Virus Res. 105:93.
- 3. Bosch, B.J. et al. (2003). J. Virol. 77:8801.
- 4. Belouzard, S. et al. (2009) Proc. Natl. Acad. Sci. 106:5871.
- 5. Millet, J.K. and G.R. Whittaker (2015) Virus Res. 202:120.
- 6. Li, W. et al. (2003) Nature 426:450.
- 7. Wong, S.K. et al. (2004) J. Biol. Chem. 279:3197.
- 8. Yadav, P.D. et al. (2021) bioRxiv https://doi.org/10.1101/2021.04.23.441101.
- 9. Cherian, S. et al. (2021) bioRxiv https://doi.org/10.1101/2021.04.22.440932.

Rev. 6/1/2021 Page 2 of 2



Global bio-techne.com info@bio-techne.com techsupport@bio-techne.com TEL +1 612 379 2956 USA TEL 800 343 7475 Canada TEL 855 668 8722 China TEL +86 (21) 52380373 Europe | Middle East | Africa TEL +44 (0)1235 529449